儿童骨髓移植后肺动脉高压的临床特征与转归
该研究回顾性分析了2008至2015年间366例接受造血干细胞移植的儿童,其中22例确诊移植后肺动脉高压,平均肺动脉压40.1±10 mmHg,7例(32%)死亡。症状出现至启动靶向治疗的时间在死亡组显著长于存活组(33.5±23天 vs 7±3天,p<0.001),及时联合治疗可使肺动脉压力正常化并改善生存。
要点
- 儿童HSCT后肺动脉高压发生率为被低估的严重并发症,本组确诊22例,死亡率32%。
- 症状至治疗延迟与死亡相关,死亡组延迟33.5±23天,存活组仅7±3天(p<0.001)。
- 及时启动联合靶向治疗可使存活者肺动脉压力正常化并最终停用肺动脉高压药物。
核心结论
- 肺动脉高压是儿童造血干细胞移植后严重且发生率被低估的并发症,死亡率高。
- 及时积极的联合治疗可使肺动脉压力正常化并改善生存。
研究设计与样本
- 移植后因呼吸道症状行超声心动图发现三尖瓣反流速度>2.8 m·s-1者31例,尽可能经右心导管确诊。
主要发现
- 22例确诊肺动脉高压,平均肺动脉压40.1±10 mmHg(范围28-62 mmHg),肺血管阻力17.3±9.2 Wood Units(范围8-42 Wood Units)。
- 13例进行反应性试验,仅1例对钙通道阻滞剂有反应。
- 7例(32%)死亡;15例存活者平均随访6.5±2.3年(范围2-10年)。
- 存活者在中位随访5个月(范围3-16个月)后均停用肺动脉高压治疗。
- 症状至启动肺动脉高压治疗的时间在死亡组为33.5±23天(中位30天),显著长于存活组的7±3天(p<0.001)。
关键数值与推荐
- 超声心动图三尖瓣反流速度>2.8 m·s-1提示需进一步评估肺动脉高压。
- 右心导管确诊的平均肺动脉压40.1±10 mmHg、肺血管阻力17.3±9.2 Wood Units。
临床怎么用
- 儿童HSCT后出现呼吸道症状应尽早行超声心动图筛查肺动脉高压。
- 确诊后应尽早启动联合肺动脉高压治疗,缩短症状至治疗延迟以改善生存。
局限性
- 回顾性单中心研究,样本量有限(确诊22例)。
- 肺动脉高压发生率可能受超声筛查策略影响而被低估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pulmonary hypertension is a rare but important cause of mortality after haematopoietic stem cell transplantation (HSCT) in children. This complication is poorly characterised in the literature. We report here a series of children who developed pulmonary hypertension after HSCT. METHODS: Between January 2008 and December 2015, we retrospectively analysed 366 children who underwent HSCT (age range 0.5-252 months; median 20.3 months). During the post-HSCT course, echocardiography scans motivated by respiratory symptoms identified 31 patients with elevated tricuspid regurgitation velocity (>2.8 m·s-1), confirmed when possible by right heart catheterisation (RHC). RESULTS: 22 patients had confirmed pulmonary hypertension with mean±sd pulmonary arterial pressure 40.1±10 mmHg (range 28-62 mmHg) and pulmonary vascular resistance 17.3±9.2 Wood Units (range 8-42 Wood Units). Among the 13 responders at reactivity test, only one patient responded to calcium channel blockers. Seven patients (32%) died. 15 pulmonary hypertension patients were alive after a mean±sd follow-up of 6.5±2.3 years (range 2-10 years). All survivors could be weaned off pulmonary hypertension treatment after a median follow-up of 5 months (range 3-16). The delay between clinical symptoms and initiation of pulmonary hypertension therapy was significantly longer in patients who subsequently died (mean±sd 33.5±23 days; median 30 days) than in survivors (mean±sd 7±3 days) (p<0.001). CONCLUSION: Pulmonary hypertension is a severe complication of HSCT with an underestimated incidence and high mortality. Aggressive and timely up-front combination therapy allowed normalisation of pulmonary pressure and improved survival.
引用
- Levy M, Moshous D, Szezepanski I, et al. Pulmonary hypertension after bone marrow transplantation in children. Eur Respir J. 2019. PMID: 31649064. doi:10.1183/13993003.00612-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。